MIF-1 Peptide Guide: Dosage, Reconstitution, Benefits & Protocol

MIF-1 Peptide (Melanocyte-Inhibiting Factor-1)

MIF-1 (Melanocyte-Inhibiting Factor-1) is a short neuroactive peptide studied for dopamine modulation, mood support, motivation, and cognitive enhancement. Unlike long-cycle peptides, MIF-1 is typically used in short bursts due to rapid neurologic adaptation and fast-acting effects.

How MIF-1 Works

Dopamine Signaling ↑ → Motivation ↑ → Mood Support ↑ → Cognitive Drive ↑

MIF-1 is believed to influence dopaminergic signaling pathways involved in reward, motivation, mood, and mental energy. It is commonly discussed as a fast-acting neuropeptide rather than a traditional stimulant.

Studied for dopamine-related signaling support

May support motivation and mental drive

Often discussed for mood and focus support

Typically cycled short-term due to fast adaptation

MIF-1 Research-Use Protocol (Short-Cycle Approach)

50 mg vial + 3.0 mL BAC Water → 1 unit = 166.7 mcg → Short-Cycle Neurologic Support

Standard Setup

Vial 50 mg

Water 3.0 mL bacteriostatic water

Concentration 16.67 mg/mL

Conversion 1 unit = 166.7 mcg

Days 1–3

Starting Phase

Dose 2.5 mg

Units 15 units

Volume 0.15 mL

Frequency 1× daily

Days 4–7

Build Phase

Dose 5 mg

Units 30 units

Volume 0.30 mL

Frequency 1× daily

Optional Extension

Higher Research-Use Range

Dose 7.5–10 mg

Units 45–60 units

Volume 0.45–0.60 mL

Duration Up to 10–14 days total

Cycle Break

Break Length 1–4 weeks

Goal Reassess response before repeating

Why short cycles?
Human MIF-1 studies have generally used relatively brief treatment periods, including consecutive daily dosing over several days. The short-cycle structure shown here reflects that research history, but no universal cycle length or required washout period has been established.

How to Use MIF-1 (Cycle, Timing & Injection)

Consistent Timing → Track Neurologic Response → Short Cycle → Break + Reassess

Administration Methods

Human Clinical Route Subcutaneous

Alternative Research Route Intranasal

Injection Areas Abdomen or thigh

Why route matters:
Published human depression research has included subcutaneous MIF-1 administration. Intranasal use is discussed in modern research settings, but evidence from subcutaneous studies should not automatically be applied to intranasal dosing.

Timing Notes

Morning dosing is most common.

Early afternoon dosing may also be used.

Avoid late-night dosing if sleep disruption occurs.

No specific fasting requirement is typically discussed.

Consistent timing makes response easier to evaluate.

Cycle Structure

Research-Use Cycle 5–10 days

Optional Extension Up to 14 days

Commonly Discussed Break 1–4 weeks

Clinical Standard No universal off-period established

Simple Approach:
MIF-1 is generally discussed in short research-use periods rather than continuous use. Human studies have evaluated brief courses, and historical research suggests that dose-response may not be linear, so higher amounts should not automatically be assumed to produce stronger effects.

Reconstitution & Dosing (50 mg + 100 mg Vials)

Small Vial Capacity → 3.0 mL BAC Water → Vial-Specific Unit Conversion

50 mg Vial — Website Standard

Vial 50 mg

Water 3.0 mL bacteriostatic water

Concentration 16.67 mg/mL

Conversion 1 unit = 0.167 mg (166.7 mcg)

Dose Reference — 50 mg Vial

2.5 mg = 15 units

5 mg = 30 units

7.5 mg = 45 units

10 mg = 60 units

100 mg Vial

Vial 100 mg

Water 3.0 mL bacteriostatic water

Concentration 33.33 mg/mL

Conversion 1 unit = 0.333 mg (333.3 mcg)

Dose Reference — 100 mg Vial

2.5 mg = 7.5 units

5 mg = 15 units

7.5 mg = 22.5 units

10 mg = 30 units

Reconstitution Steps

Draw 3.0 mL bacteriostatic water

Inject slowly down the vial wall

Gently swirl (do not shake)

Allow solution to fully dissolve

Refrigerate immediately after mixing

Protect from light and heat

Important:
MIF-1 is commonly sold in higher-strength 50 mg and 100 mg vials that still use small vial formats. This guide therefore uses 3.0 mL bacteriostatic water for both vial sizes. Because the 100 mg vial is twice as concentrated, its syringe-unit conversions are different from the 50 mg vial.

Storage & Shelf Life

Storage & Stability

Lyophilized (Unmixed)

Refrigerate short-term at 2–8°C / 36–46°F

Freeze long-term at −20°C / −4°F

Protect from moisture and heat exposure

Reconstituted (Mixed)

Store refrigerated at 2–8°C / 36–46°F

Best used within ~30 days

Avoid repeated warming cycles

Discard if cloudy, discolored, or visibly contaminated

Why MIF-1 Is Different

Dopamine-Related Signaling → Mood + Neurobehavioral Research → Short-Course Clinical Research

MIF-1 is a small neuroactive tripeptide rather than a growth or recovery peptide.

Human research has primarily focused on mood and neurologic conditions.

Dopamine-related signaling is an important area of mechanistic research.

Historical clinical studies generally evaluated relatively short treatment courses.

Key distinction
MIF-1 is commonly viewed as a neuroregulatory peptide focused on mood, motivation, and dopamine-related signaling rather than tissue repair or hormone optimization.

Monitoring During Use

Mood and emotional response

Motivation and mental drive

Focus and cognitive clarity

Sleep quality and overstimulation

Tolerance and changes in response over time

Benefits

Human clinical research has evaluated MIF-1 for depressive symptoms

Older studies reported relatively rapid mood-related responses in some participants

Experimental research supports interactions with dopamine-related signaling

Neurobehavioral and neurologic effects remain active areas of research

Modern large-scale clinical evidence remains limited

Potential Side Effects

Injection-site irritation may occur with subcutaneous administration

Headache, irritability, or changes in alertness may occur

Mood or neurologic response may vary between individuals

Modern human safety data remain limited

Long-term safety of repeated research-use cycles has not been established

Stacking Strategies

MIF-1 → Dopamine Support
Semax → BDNF & Focus
Selank → Stress Regulation

Common Pairings

Nootropic Research: MIF-1 + Semax

Mood / Stress Research: MIF-1 + Selank

Stacking Considerations

MIF-1 is sometimes discussed alongside other neuroactive compounds such as Semax or Selank.

Controlled human research has not established specific MIF-1 combination protocols.

Combining multiple neuroactive compounds can make individual effects harder to evaluate.

Evidence for one compound should not automatically be interpreted as evidence for a combined stack.

Important Notes

MIF-1 (Pro-Leu-Gly-NH₂) is a naturally occurring neuroactive tripeptide with historical human clinical research.

Subcutaneous MIF-1 has been evaluated in human depression studies, including short courses of daily administration.

Historical research suggests MIF-1 may have a non-linear or inverted U-shaped dose-response, so higher doses should not automatically be assumed to produce greater effects.

Modern large-scale clinical research remains limited, and historical findings should not be treated as an established contemporary treatment protocol.

No universal human dose, cycle length, maintenance schedule, or required off-period has been established.

50 mg and 100 mg vials require different unit conversions when both are reconstituted with 3.0 mL.

Important Disclaimer

MIF-1 is an investigational peptide and not FDA-approved. This content is for educational purposes only and does not constitute medical advice.

MIF-1 Guide → Peptide Directory →